Production of retroviral vectors for clinical use

Kenneth Cornetta, Lilith Reeves, Scott Cross

Research output: Chapter in Book/Report/Conference proceedingChapter

6 Scopus citations

Abstract

Retroviral vectors were the first viral vectors to enter clinical trials and continue to be attractive candidates for applications where integration of the transgene is required. While these vectors are versatile and are used widely in the research setting, large-scale production for human use poses various challenges to insure quality and high titer. Our vector production facility has produced and certified over 20 vectors for clinical use and continues to be challenged to adapt the ever-changing vector technology to a method of production that complies with Good Manufacturing Practice (GMP). We describe two manufacturing methods for producing material for Phase I/II clinical trials and suggest ways for investigators to adapt these methods for multiple applications.

Original languageEnglish (US)
Title of host publicationGene Therapy Protocols
Subtitle of host publicationProduction and In Vivo Applications of Gene Transfer Vectors
PublisherHumana Press
Pages17-32
Number of pages16
ISBN (Print)9781588299031
DOIs
StatePublished - Jan 1 2008

Publication series

NameMethods in Molecular Biology
Volume433
ISSN (Print)1064-3745

    Fingerprint

Keywords

  • Gene therapy
  • Good Manufacturing Practice
  • Packaging cell line
  • Retroviral vectors
  • Transient transfection

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

Cornetta, K., Reeves, L., & Cross, S. (2008). Production of retroviral vectors for clinical use. In Gene Therapy Protocols: Production and In Vivo Applications of Gene Transfer Vectors (pp. 17-32). (Methods in Molecular Biology; Vol. 433). Humana Press. https://doi.org/10.1007/978-1-59745-237-3_2